Recombinant Interleukin-6 - Sonnet Biotherapeutics Holdings
Alternative Names: atexakin alfa; r-IL-6; recombinant IL-6; SON 080; SON-081Latest Information Update: 26 Apr 2024
At a glance
- Originator Weizmann Institute of Science
- Developer RELIEF THERAPEUTICS Holding; Sonnet BioTherapeutics Holdings, Inc; Xequel Bio
- Class Antineoplastics; Interleukins
- Mechanism of Action Interleukin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Peripheral nerve injuries
- Phase I Diabetic neuropathies
Most Recent Events
- 12 Apr 2024 Sonnet BioTherapeutics terminates a phase I/II trial in Peripheral nerve injuries in Australia (SC), due to lack of enrolment (NCT05435742)
- 05 Apr 2024 Pharmacodynamics and safety data from preclinical studies in Diabetic-neuropathies presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 17 Jan 2024 Phase-I development in Diabetic-neuropathies is ongoing in Switzerland and USA (Parenteral) (Sonnet BioTherapeutics Holdings pipeline, January 2024)